Orocalm (Benzydamine Hydrochloride)

Benzydamine Hydrochloride inhibits prostaglandin synthesis and stabilises cell membranes, which reduces inflammation and pain. It also has mild antimicrobial properties that help control oral micro‑flora, providing a combined anti‑inflammatory, analgesic and antiseptic effect.

The dosage of Orocalm is determined by the prescribing healthcare professional based on the patient’s age, severity of symptoms and clinical judgment. Patients should follow the specific instructions provided on the prescription label or by their clinician.

Safety data for Benzydamine Hydrochloride in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using Orocalm.

To request Orocalm, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with systemic NSAIDs, Orocalm provides a targeted local effect, minimizing systemic exposure and related adverse events. Unlike some antiseptic mouthwashes, benzydamine combines anti‑inflammatory, analgesic and antimicrobial actions in a single formulation, offering broader symptom relief for oral inflammation.

Store Orocalm at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed when not in use.

Orocalm is applied directly to the affected oral mucosa. The patient should dispense the recommended amount onto the tongue or affected area, allow it to stay in contact for the prescribed time, and avoid eating or drinking for a short period afterward as advised by the prescriber.

The most serious risks include allergic reactions such as urticaria, angioedema or anaphylaxis, and severe oral ulceration or necrosis. Patients should seek immediate medical attention if they experience swelling of the face, lips, tongue, difficulty breathing, or persistent worsening of oral lesions.

Individuals with a known hypersensitivity to benzydamine hydrochloride or any component of the formulation should avoid using Orocalm. It is also contraindicated in patients who have experienced severe allergic reactions to similar topical NSAIDs, unless directed otherwise by a healthcare professional.